Acalabrutinib (CALQUENCE®) is a novel experimental anti-cancer drug and a 2nd generation Bruton's tyrosine kinase inhibitor developed by Acerta Pharma. It is more potent and selective than ibrutinib, the first-in-class BTK inhibitor.
Our Medication Sheet
This sheet is coming soon. check back later to download it as an Adobe PDF.